Form 4: Twist Bioscience CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Emily M. Leproust, CEO of Twist Bioscience, sold 5,585 shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- Emily M. Leproust, CEO of Twist Bioscience, sold 5,585 shares of common stock on August 4, 2025, at a price of $28.364 per share.
- The sale was mandated by the Issuer's election under its equity incentive plans to cover tax withholding obligations related to the vesting of Restricted Stock Units.
- Following the transaction, Leproust directly owns 639,721 shares of Twist Bioscience common stock.
- Leproust also holds options to purchase shares of common stock at various exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing is a routine disclosure of stock transactions for tax purposes.
Positives
- The filing provides transparency regarding the CEO's stock transactions.
- The filing clarifies the reason for the sale, which is to cover tax obligations related to vesting Restricted Stock Units and not a discretionary trade.
Negatives
- The sale of shares by the CEO, even for tax obligations, could be perceived negatively by some investors.
Risks
- There are no specific risks mentioned in this filing.
Future Outlook
There are no explicit forward-looking statements in this filing.
Management Comments
- The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.
Industry Context
This filing is a routine disclosure related to executive stock transactions, which is common for publicly traded companies. It does not provide specific insights into the broader industry trends.
Comparison to Industry Standards
- Executive compensation and stock ownership are standard practices in publicly traded companies, including competitors like Agilent Technologies (A) and Illumina (ILMN).
- Sell-to-cover transactions for tax obligations are a common mechanism in equity compensation plans across the industry.
- The specific details of equity compensation plans vary from company to company.
Stakeholder Impact
- The sale of shares could have a minor negative impact on shareholder sentiment, although it is primarily for tax obligations.
Next Steps
- None mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 08/04/2025 | Date of stock sale transaction. |
| 08/06/2025 | Date of filing. |
| 09/28/2025 | Expiration date for Employee Stock Option (right to buy) with exercise price of $5.95. |
| 09/28/2027 | Expiration date for Employee Stock Option (right to buy) with exercise price of $8.82. |
| 11/18/2028 | Expiration date for Employee Stock Option (right to buy) with exercise price of $26.66. |
| 10/23/2029 | Expiration date for Employee Stock Option (right to buy) with exercise price of $23.33. |
| 08/31/2030 | Expiration date for Employee Stock Option (right to buy) with exercise price of $67.85. |
Keywords
Twist Bioscience, TWST, Emily Leproust, CEO, stock sale, Form 4, SEC filing, tax obligations, Restricted Stock Units, equity incentive plans
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.